RNS Number : 1380C AOTI, Inc. 25 March 2025 25 March 2025 AOTI, INC. (the "Company" or "Group" or "AOTI") Director/PDMR Shareholding - transfer of shares to SIPP The Company was informed on 25 March 2025 that Mr Douglas Lefort, Non-executive Chairman of the Company and his spouse, transferred a total of 361,453 common shares of $0.00001 each in the capital of the Company ("Common Shares") into their Self-Invested Personal Pensions ("SIPPs") from their jointly owned consulting vehicle, Wolfpack Consulting Limited. This was effected by the purchase and sale of 194,117 Common Shares at 102.5 pence each on 20 March 2025 by Mr Lefort and the purchase and sale of 167,336 Common Shares at 95 pence each on 25 March 2025 by Mrs Lefort. Following the purchase and sale transactions, there is no change to Mr Lefort's beneficial holding (including that of his spouse) and the total interest in the Company remains the same at 1,451,621 Common Shares, representing approximately 1.36% of the Company's issued share capital. The below notification, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail. END For further information please contact: ABOUT AOTI, INC. AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHBRGDXLUDDGUU